Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript

Core Points - The company announced positive results from its Phase III PEAK trial in GIST, which were shared in a press release [2] Group 1 - The webcast was hosted by Christi Waarich, Senior Director of Investor Relations, who introduced the call and highlighted the positive trial results [2][4] - The company provided a reminder that remarks made during the webcast may include forward-looking statements, particularly regarding regulatory submissions and clinical data [3]